EHA 2022 | Inotuzumab ozogamicin for MRD-positive B-ALL
Jayastu Senapati
• 13 Jun 2022
Jayastu Senapati, MBBS, MD, MD Anderson Cancer Center, Houston, TX, discusses the results of a Phase II study investigating the use of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive (Ph+ALL) and negative (Ph-) B-cell acute lymphoblastic leukemia (B-ALL) who are measurable residual disease (MRD)-positive. Whilst the study reported promising overall response rates (ORR), it did not meet its primary endpoint. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
